Nephros Resultados de beneficios anteriores
Pasado controles de criterios 3/6
Nephros ha aumentado sus beneficios a una tasa media anual de 57.2%, mientras que los beneficios de la industria de Machinery han experimentado un crecimiento de 9.2% anual. Los ingresos han ido creciendo a una tasa media de 15.9% al año. La rentabilidad financiera de Nephros es de 14.5%, y sus márgenes netos son de 8.4%.
Información clave
57.24%
Tasa de crecimiento de los beneficios
57.71%
Tasa de crecimiento del BPA
| Crecimiento de la industria Machinery | 8.77% |
| Tasa de crecimiento de los ingresos | 15.87% |
| Rentabilidad financiera | 14.51% |
| Margen neto | 8.38% |
| Última actualización de beneficios | 30 Jun 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
NEPH: Index Additions And M&A Options Will Shape Balanced Future Outlook
Nephros has seen its analyst price target move from about $4.00 to roughly $4.75, with analysts citing expectations for higher revenue growth and stronger profit margins. They also recognize its five nanometer ultrafilter as a key product, while monitoring for growth to reaccelerate beyond 20%.
NEPH: Index Additions And Water Filtration Leadership Will Support Future Upside
Analysts trimmed their fair value estimate for Nephros from $7 to $6, citing a higher future P/E assumption of about 50x and a weaker profit margin outlook. They also highlight the company's five nanometer ultrafilter and indicate they would like to see revenue growth trends improve further before becoming more positive on the stock.NEPH: Index Additions And Mergers Will Shape Future Trading Profile
Analysts now see Nephros shares fairly valued closer to $4.00 per share, aligning with a new $4 price target that reflects confidence in its ultrafilter technology, while also recognizing that recent gains already capture much of the anticipated growth until revenue expansion re-accelerates above 20%. What’s in the News for Nephros Nephros is actively seeking acquisitions, merger partners, and business development investments, with management indicating an interest in opportunities that they view as offering a significantly higher return on investment, source: Nephros investor event.Nephros, Inc. (NASDAQ:NEPH) Just Reported And Analysts Have Been Lifting Their Price Targets
It's been a pretty great week for Nephros, Inc. ( NASDAQ:NEPH ) shareholders, with its shares surging 15% to US$3.52 in...Is Nephros, Inc. (NASDAQ:NEPH) Potentially Undervalued?
Nephros, Inc. ( NASDAQ:NEPH ), might not be a large cap stock, but it saw a decent share price growth of 19% on the...Nephros, Inc.'s (NASDAQ:NEPH) Popularity With Investors Under Threat As Stock Sinks 28%
Nephros, Inc. ( NASDAQ:NEPH ) shareholders won't be pleased to see that the share price has had a very rough month...Is It Time To Consider Buying Nephros, Inc. (NASDAQ:NEPH)?
Nephros, Inc. ( NASDAQ:NEPH ), is not the largest company out there, but it received a lot of attention from a...Nephros (NASDAQ:NEPH) Is Experiencing Growth In Returns On Capital
There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a...Why Investors Shouldn't Be Surprised By Nephros, Inc.'s (NASDAQ:NEPH) 27% Share Price Surge
Nephros, Inc. ( NASDAQ:NEPH ) shareholders would be excited to see that the share price has had a great month, posting...At US$4.26, Is Nephros, Inc. (NASDAQ:NEPH) Worth Looking At Closely?
Nephros, Inc. ( NASDAQ:NEPH ), is not the largest company out there, but it saw a significant share price rise of 47...It's Down 26% But Nephros, Inc. (NASDAQ:NEPH) Could Be Riskier Than It Looks
NasdaqCM:NEPH 1 Year Share Price vs Fair Value Explore Nephros's Fair Values from the Community and select yours...Nephros, Inc.'s (NASDAQ:NEPH) 79% Jump Shows Its Popularity With Investors
Despite an already strong run, Nephros, Inc. ( NASDAQ:NEPH ) shares have been powering on, with a gain of 79% in the...Should You Think About Buying Nephros, Inc. (NASDAQ:NEPH) Now?
Nephros, Inc. ( NASDAQ:NEPH ), is not the largest company out there, but it led the NASDAQCM gainers with a relatively...Investors Still Aren't Entirely Convinced By Nephros, Inc.'s (NASDAQ:NEPH) Revenues Despite 32% Price Jump
Nephros, Inc. ( NASDAQ:NEPH ) shares have had a really impressive month, gaining 32% after a shaky period beforehand...It's A Story Of Risk Vs Reward With Nephros, Inc. (NASDAQ:NEPH)
There wouldn't be many who think Nephros, Inc.'s ( NASDAQ:NEPH ) price-to-sales (or "P/S") ratio of 1.2x is worth a...We're Not Worried About Nephros' (NASDAQ:NEPH) Cash Burn
We can readily understand why investors are attracted to unprofitable companies. For example, although...Nephros, Inc. (NASDAQ:NEPH) Just Reported And Analysts Have Been Cutting Their Estimates
Shareholders might have noticed that Nephros, Inc. ( NASDAQ:NEPH ) filed its quarterly result this time last week. The...After Leaping 40% Nephros, Inc. (NASDAQ:NEPH) Shares Are Not Flying Under The Radar
Nephros, Inc. ( NASDAQ:NEPH ) shares have continued their recent momentum with a 40% gain in the last month alone. The...At US$3.18, Is It Time To Put Nephros, Inc. (NASDAQ:NEPH) On Your Watch List?
Nephros, Inc. ( NASDAQ:NEPH ), might not be a large cap stock, but it received a lot of attention from a substantial...Desglose de ingresos y gastos
Cómo gana y gasta dinero Nephros. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 26 | 21 | 2 | 9 | 1 |
| 31 Mar 26 | 19 | 1 | 9 | 1 |
| 31 Dec 25 | 19 | 1 | 9 | 1 |
| 30 Sep 25 | 18 | 1 | 9 | 1 |
| 30 Jun 25 | 17 | 1 | 8 | 1 |
| 31 Mar 25 | 16 | 1 | 8 | 1 |
| 31 Dec 24 | 14 | 0 | 8 | 1 |
| 30 Sep 24 | 14 | -1 | 8 | 1 |
| 30 Jun 24 | 14 | -1 | 9 | 1 |
| 31 Mar 24 | 14 | -1 | 9 | 1 |
| 31 Dec 23 | 14 | -2 | 9 | 1 |
| 30 Sep 23 | 14 | -2 | 8 | 1 |
| 30 Jun 23 | 12 | -3 | 8 | 1 |
| 31 Mar 23 | 12 | -3 | 8 | 1 |
| 31 Dec 22 | 10 | -5 | 8 | 1 |
| 30 Sep 22 | 10 | -5 | 8 | 1 |
| 30 Jun 22 | 10 | -4 | 7 | 1 |
| 31 Mar 22 | 10 | -4 | 7 | 1 |
| 31 Dec 21 | 10 | -3 | 7 | 1 |
| 30 Sep 21 | 10 | -3 | 7 | 2 |
| 30 Jun 21 | 9 | -4 | 7 | 2 |
| 31 Mar 21 | 9 | -4 | 7 | 3 |
| 31 Dec 20 | 9 | -5 | 6 | 3 |
| 30 Sep 20 | 9 | -4 | 7 | 3 |
| 30 Jun 20 | 10 | -4 | 7 | 3 |
| 31 Mar 20 | 11 | -3 | 7 | 3 |
| 31 Dec 19 | 10 | -3 | 6 | 3 |
| 30 Sep 19 | 9 | -4 | 6 | 3 |
| 30 Jun 19 | 7 | -4 | 5 | 2 |
| 31 Mar 19 | 6 | -3 | 5 | 2 |
| 31 Dec 18 | 6 | -3 | 4 | 2 |
| 30 Sep 18 | 5 | -1 | 4 | 1 |
| 30 Jun 18 | 5 | -1 | 4 | 1 |
| 31 Mar 18 | 4 | -2 | 4 | 1 |
| 31 Dec 17 | 4 | -1 | 3 | 1 |
| 30 Sep 17 | 3 | -3 | 3 | 1 |
| 30 Jun 17 | 3 | -3 | 3 | 1 |
| 31 Mar 17 | 2 | -3 | 3 | 1 |
| 31 Dec 16 | 2 | -3 | 3 | 1 |
| 30 Sep 16 | 2 | -3 | 3 | 1 |
| 30 Jun 16 | 2 | -3 | 3 | 1 |
| 31 Mar 16 | 2 | -4 | 3 | 1 |
| 31 Dec 15 | 2 | -3 | 3 | 1 |
| 30 Sep 15 | 2 | -3 | 3 | 1 |
Ingresos de calidad: NEPH tiene un alto nivel de ganancias no monetarias.
Margen de beneficios creciente: Los actuales márgenes de beneficio (8.4%) de NEPH son superiores a los del año pasado (8%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: NEPH ha pasado a ser rentable en los últimos 5 años, con un crecimiento de los beneficios de 57.2% al año.
Acelerando crecimiento: El crecimiento de los beneficios de NEPH en el último año (30.8%) está por debajo de su media de 5 años (57.2% al año).
Beneficios vs. Industria: El crecimiento de los beneficios de NEPH en el último año (30.8%) superó al de la industria Machinery 8.5%.
Rentabilidad financiera
Alta ROE: La rentabilidad financiera de NEPH (14.5%) se considera baja.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/21 02:35 |
| Precio de las acciones al final del día | 2026/09/21 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Nephros, Inc. está cubierta por 4 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Marc Wiesenberger | B. Riley Securities, Inc. |
| Anthony Vendetti | Maxim Group |
| Robert Brooks | Northland Capital Markets |